Jazz Pharma Reports Top-Line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness: Achieved Primary, Key Secondardy Endpoints
Benzinga Newsdesk